Last Modified: September 7, 2010
Conference Dates: October 8-10, 2010
Conference Location: Sheraton New York Hotel Towers
Conference Web Page URL: www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/530
Topics Covered: The Ninth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy congress will address emerging data that underlie the optimal management of early-stage and locally advanced breast cancer. The congress will include an in-depth discussion of the increasing number of breast cancer subtypes that challenge oncologists. A significant emphasis on case discussions and new data supporting adjuvant and neoadjuvant treatment options will provide a forum for discussion of the practical applicability of evolving clinical trial findings. Other topics pertaining to predictive biomarkers, staging, risk assessment, toxicity management, and survivorship will also be addressed.
Registration Information: For registration assistance, please email CustomerSupport@CancerLearning.com, or call (888) 949-0045.
Conference Fees: $395.00
Continuing Education: Yes
Feb 1, 2010 - In women with HER2-positive locally advanced or inflammatory breast cancer, adding neoadjuvant and adjuvant trastuzumab to neoadjuvant chemotherapy may improve event-free survival, according to a study in the Jan. 30 issue of The Lancet.
Aug 10, 2010